Carl Zeiss Meditec AG (XTRA:AFX) signed an agreement to acquire Dutch Ophthalmic Research Center (International) B.V. from Eurazeo China Acceleration Fund and Eurazeo Capital IV funds managed by Eurazeo SE (ENXTPA:RF) on December 15, 2023. The transaction is valued at an enterprise value of approximately ?985 million. The purchase price will be paid for primarily by available net liquidity of Carl Zeiss Meditec AG. In order to maintain operational flexibility, company plans to seek a shareholder loan from carl zeiss ag in amount of ?400 million as part of financing, with a duration of three years and market-standard conditions. The acquisition should achieve a modest positive contribution (by a single digit percentage amount) to earnings per share of carl zeiss meditec ag in first full year after closing. The acquisition subject to applicable regulatory and antitrust approvals and is expected to close in the first half of calendar year 2024. RBC Capital Markets served as exclusive financial advisor to Carl Zeiss Meditec AG (XTRA:AFX) in the transaction. Latham & Watkins LLP, Antoinette van der Hauw, Bastiaan Cornelisse, Louis Lutz of Loyens & Loeff N.V. and Imme Khan of Loyens & Loeff acted as legal advisors to Eurazeo SE. Roman Tarlavski, Gijs Langerak, Edmon Oude Elferink, Annemieke Hazelhoff, Iris Zeilstra,
Herman Boersen, Jarrik Haust, Marcellina Rietvelt, Florine Goemans, Maarten Feenstra, Robert Jong of CMS Derks Star Busmann N.V. acted as legal advisor to Carl Zeiss Meditec AG.

Carl Zeiss Meditec AG (XTRA:AFX) completed the acquisition of Dutch Ophthalmic Research Center (International) B.V. from Eurazeo China Acceleration Fund and Eurazeo Capital IV funds managed by Eurazeo SE (ENXTPA:RF) on April 3, 2024. All regulatory approvals received.